ada-transduced cd34+ cells
Cell therapyexperimental
Clinical trial activity
8 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
6
Phase 3
0
Phase 4
1
Earliest trial started Mar 1, 1992 (NCT00599781)
Timeline
Indications
Approved for
Mechanism of action
- Adenosine deaminaseSupplementation
ADA supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ada transduced cells
- adenosine deaminase gene transduced hsc
- adenosine deaminase gene transduced pbl
- adenosine deaminase transduced hematopoietic progenitors
- autologous cd34+ enriched cell fraction that contains cd34+ cells transduced with retroviral vector that encodes for the human adenosine deaminase (ada) cdna sequence from human haematopoietic stem/progenitor (cd34+) cells
- autologous efs-ada lv cd34+ cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05432310 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2023 | University of California, Los Angeles |
| NCT03311074 | Phase 4 | Oct 31, 2018 | GlaxoSmithKline, PPD |
| NCT03765632 | Phase 1/Phase 2 (Phase 2) | Jan 2, 2018 | University of London |
| NCT02999984 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2016 | California Institute for Regenerative Medicine, Orchard Therapeutics Limited, University of California, Los Angeles, University of London |
| NCT02022696 | Phase 1 | Dec 16, 2013 | Duke University, National Cancer Institute (NCI), National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH) |
| NCT01279720 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2003 | University of London |
| NCT00598481 | Phase 2 | Oct 2, 2002 | GlaxoSmithKline |
| NCT00599781 | Phase 1/Phase 2 (Phase 2) | Mar 1, 1992 | Fondazione Telethon, Vita-Salute University of Milano. Italy |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of London | Academic/Hospital | 3 | 2 | 1 | 2003 |
| GlaxoSmithKline | For profit | 2 | 2 | 2 | 2002 |
| University of California, Los Angeles | Academic/Hospital | 2 | 2 | 1 | 2016 |
| California Institute for Regenerative Medicine | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Fondazione Telethon | Academic/Hospital | 1 | 0 | 1 | 1992 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2013 |
| National Human Genome Research Institute (NHGRI) | Government | 1 | 1 | 1 | 2013 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2013 |
| Orchard Therapeutics Limited | For profit | 1 | 0 | 1 | 2016 |
| PPD | For profit | 1 | 0 | 1 | 2018 |
| Vita-Salute University of Milano. Italy | Academic/Hospital | 1 | 1 | 1 | 1992 |
12 organizations
Page 1 / 1